Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Zachary BessetteAdvanced Renal Cell Carcinoma | December 6, 2022
For patients with mRCC, durable complete response to sunitinib can be achieved irrespective of prognostic group...
Read More
Emily MenendezAdvanced Renal Cell Carcinoma | December 6, 2022
Patients with mccRCC and high body mass index may experience better outcomes when treated with immune checkpoint blockades.
Leah LawrenceESMO 2022 | September 16, 2022
CLEAR study results showed that treatment with first-line lenvatinib plus pembrolizumab had clinical benefit at 2 years.
Leah LawrenceAdvanced Renal Cell Carcinoma | August 2, 2022
When detecting genetic alterations in patients, only 24 alterations were found by MSK-IMPACT in seven of 110 patients.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 21, 2022
Study results demonstrate a conclusive pattern of distinct molecular alterations among metastatic sites in patients with RCC.
The UromigosThe Uromigos | December 21, 2021
Chad Tang discusses his oncology paper recently published in Lancet.
Robert DillardJournal | December 14, 2021
Minimal increase in palliative care use for patients with Stage IV RCC highlights need for more awareness, earlier ...
GU Oncology Now EditorsJournal | December 14, 2021
The results of the CLEAR trial were published simultaneously in The New England Journal of Medicine.
Robert DillardAdvanced Renal Cell Carcinoma | September 3, 2021
Dr. Atkins discusses a study he was involved in on nivolumab + ipilimumab for renal cell carcinoma.
The UromigosThe Uromigos | April 9, 2021
Dr. Viktor Grünwald discusses treatment for progression of disease after front-lines PD1-based therapy.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 26, 2021
The phase 3 CLEAR trial showed improved OS for lenvatinib plus pembrolizumab as first-line therapy for advanced RCC.
The UromigosThe Uromigos | February 11, 2020
David McDermott explains how he chooses between ipilimumab/nivolumab or axitinib/pebrolizumab in treatment options.